Compound Encyclopedia

This is an index of every compound AVERON carries, written the same way for each one. Each page opens with an evidence level, then explains what the compound is in plain language, what researchers have studied it for, what the published research found, what it does not do and what is still unknown, which adverse effects were reported in studies, and its regulatory and anti-doping status. At the bottom of each page you will find the sources and a link to the independent lab report for that compound.

How to read an evidence level

The badge at the top of each page tells you how much is actually known.

Approved Medicine means a government regulator has approved the compound, in a specific form, for a specific condition. It does not mean it is approved for anything else, and the research-grade material AVERON supplies is not the branded, registered product.

Human Trial Data means published phase 2 or phase 3 trials in people exist, but no regulator has approved it.

Early Human Data means only small, short, or early studies in people exist, or human evidence is limited to one form of use.

Preclinical Only means the evidence comes from cell or animal studies. There are no controlled human trials showing benefit.

Which compounds are approved medicines

Six compounds in our catalog are approved medicines somewhere in the world, each only in a specific form and for a specific condition:

• Tirzepatide — approved as Mounjaro and Zepbound in several countries.
• Semaglutide — approved as Ozempic and Wegovy in several countries.
• Tesamorelin — approved in the United States as Egrifta, for excess abdominal fat in people with HIV-associated lipodystrophy.
• Bremelanotide (PT-141) — approved in the United States as Vyleesi, for a specific form of low sexual desire in premenopausal women.
• Afamelanotide (Melanotan I) — approved as Scenesse, a clinician-placed implant, for a rare light-sensitivity disorder called erythropoietic protoporphyria.
• Elamipretide (SS-31) — approved in the United States in 2025 as Forzinity, for Barth syndrome, a rare genetic disease.

Every other compound in the catalog is either in clinical trials or has only early or preclinical evidence. Each page says which.

A note on sport

If you compete in a tested sport, check each page's anti-doping section before anything else. Several compounds we carry are on the World Anti-Doping Agency's Prohibited List, including some that people often assume are allowed. Compounds that have no approval for human therapeutic use anywhere fall under WADA's category S0, which is prohibited at all times.

The compounds

Compound pages are being added in stages. New pages appear here automatically.